Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q2 2020 (← Previous) (Next →)

Filing Date: Jul 20, 2020

Total Value: $696.1B (100.0% shares, 0.0% debt)

Holdings (12)

CRSP CRISPR Therapeutics AG 44.2%

Value $307.4B Shares 4,183,064 Est. Cost $40.26 Unrealized +45.2%

— Adverum Biotechnologies, Inc. 21.0%

Value $146.2B Shares 7,003,892 Est. Cost $9770.00 Unrealized —

— Aprea Therapeutics, Inc. 10.3%

Value $71.91B Shares 1,854,229 Est. Cost $38780.00 Unrealized —

— Akero Therapeutics, Inc. 7.6%

Value $52.72B Shares 2,115,454 Est. Cost $21200.00 Unrealized —

CRNX Crinetics Pharmaceuticals, Inc. 5.1%

Value $35.58B Shares 2,030,616 Est. Cost $17.05 Unrealized 0.0%

VCYT Veracyte, Inc. 4.5%

Value $31.22B Shares 1,205,407 Est. Cost $11.03 Unrealized +125.9%

— Gritstone Oncology, Inc. 3.0%

Value $20.6B Shares 3,102,929 Est. Cost $11140.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 2.7%

Value $18.45B Shares 2,215,384 Est. Cost $20.09 Unrealized -67.0%

— IVERIC bio, Inc. 1.3%

Value $8.797B Shares 1,724,909 Est. Cost $5100.00 Unrealized —

— CymaBay Therapeutics, Inc. 0.3%

Value $1.898B Shares 543,753 Est. Cost $9871.60 Unrealized —

— Clovis Oncology, Inc. 0.1%

Value $688M Shares 101,855 Est. Cost $56000.00 Unrealized —

— Second Sight Medical Products, Inc. 0.1%

Value $550M Shares 561,612 Est. Cost $1210.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	4,183,064	$307.4B	44.2%	$40.26	+45.2%	Common Stock	H17182108
—	Adverum Biotechnologies, Inc.	7,003,892	$146.2B	21.0%	$9770.00	—	Common Stock	00773U108
—	Aprea Therapeutics, Inc.	1,854,229	$71.91B	10.3%	$38780.00	—	Common Stock	03836J102
—	Akero Therapeutics, Inc.	2,115,454	$52.72B	7.6%	$21200.00	—	Common Stock	00973Y108
CRNX	Crinetics Pharmaceuticals, Inc.	2,030,616	$35.58B	5.1%	$17.05	0.0%	Common Stock	22663K107
VCYT	Veracyte, Inc.	1,205,407	$31.22B	4.5%	$11.03	+125.9%	Common Stock	92337F107
—	Gritstone Oncology, Inc.	3,102,929	$20.6B	3.0%	$11140.00	—	Common Stock	39868T105
OCUL	Ocular Therapeutix, Inc.	2,215,384	$18.45B	2.7%	$20.09	-67.0%	Common Stock	67576A100
—	IVERIC bio, Inc.	1,724,909	$8.797B	1.3%	$5100.00	—	Common Stock	46583P102
—	CymaBay Therapeutics, Inc.	543,753	$1.898B	0.3%	$9871.60	—	Common Stock	23257D103
—	Clovis Oncology, Inc.	101,855	$688M	0.1%	$56000.00	—	Common Stock	189464100
—	Second Sight Medical Products, Inc.	561,612	$550M	0.1%	$1210.00	—	Common Stock	81362J100